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ABSTRACT
Background and Objective. Incidence of andmortality rates for
breast cancer continue to rise in the People’s Republic of China.
The purpose of this study was to analyze differences in
characteristicsofbreastmalignanciesbetweenChinaandtheU.S.
Methods. Data from384,262breastcancerpatients registered
in the U.S. Surveillance, Epidemiology, and End Results (SEER)
program from 2000 to 2010 were compared with 4,211
Chinese breast cancer patients registered in a Chinese
database from 1999 to 2008. Outcomes included age, race,
histology, tumor and node staging, laterality, surgical treat-
mentmethod, and reconstruction.ThePearson chi-square and
Fisher’s exact tests were used to compare rates.
Results. Infiltrating ductal carcinoma was the most common
type ofmalignancy in the U.S. and China.Themean number of
positive lymph nodes was higher in China (2.59 vs. 1.31, p ,
.001). Stage at diagnosiswas higher in China (stage IIA vs. I,p,
.001). Mean size of tumor at diagnosis was higher in China
(32.63 vs. 21.57 mm). Mean age at diagnosis was lower in
China (48.28 vs. 61.29 years, p , .001). Moreover, 2.0% of
U.S. women underwent radical mastectomy compared with
12.5% inChina, and0.02% inChinaunderwent reconstructive
surgery.
Conclusion. Chinese women were diagnosed at younger ages
with higher stage and larger tumors and underwent more
aggressive surgical treatment. Prospective trials should be
conducted to address screening, surgical, and tumor discrep-
ancies between China and the U.S. The Oncologist 2015;
20:1044–1050
Implications for Practice: Breast cancer patients in China are diagnosed at later stages than those in America, which might
contributetodifferentclinicalmanagementand lower5-yearsurvival rate.Thisphenomenonsuggeststhatanearlierdetectionand
treatment program should be widely implemented in China. By comparing the characteristics of Chinese and Chinese-American
patients, we found significant differences in tumor size, lymph nodes metastasis, and age at diagnosis. These consequences
indicated that patients with similar genetic backgrounds may have different prognoses due to the influence of environment and
social economic determinates.
INTRODUCTION
Breast cancermaintains one of the highest incidences per year
among common cancers, and physicians worldwide struggle
with determining the optimal course of screening, diagnosis,
and treatmentmethods for patients.With heavy international
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focus on breast cancer research, progress continues to be
made to alleviate mortality and morbidity rates from breast
cancer. Because of increased education and screening,
deaths per 100,000 breast cancer patients in the U.S. have
decreased from 33.2 in 1989 to 21.9 in 2009 [1]. Diagnosis is
often made during annual screening visits and less often by
patient self-examination. With earlier diagnoses and sub-
sequent lower stage tumors, treatment can entail lumpec-
tomy and/or radiation and chemotherapy rather than the
more aggressive modified radical mastectomy for later,
higher stage diagnoses.
In contrastwith the decreasing rates of breast cancer-related
mortality in the U.S., multiple recent studies have illustrated
stable or increasing rates of mortality over the past few years in
the People’s Republic of China. Although 5-year survival rates for
breast cancer patients in the U.S. have increased from 84.3% in
1989 to 90.5% in 2005, those in China have remained around
76%–82% [1–3]. This difference could be related to the U.S.
maintaining well-supported national screening protocols, easy
access to breast surgeons, and a lack of a negative social stigma
surrounding screening and treatment. Given the population of
China,mortality ratesduetobreastcancerconstituteasignificant
portion of the international burden of breast cancer. Many of
these deaths are preventable with earlier identification and
treatment. Many studies have described specific characteristics
ofbreastmalignancies inChina;however,nodescriptivestudyhas
been conducted comparingbreast cancer characteristics inChina
and the U.S.
The aims of this paper are twofold. First, through
a systematic comparison of data from the U.S. Surveillance,
Epidemiology, and End Results (SEER) program from 2000 to
2010 [1] and a similar database created at the Cancer
Institute andHospital, Chinese AcademyofMedical Sciences
(CICAMS) in Beijing, China, from 1999 to 2008, we aimed to
analyze differences between the two nations pertaining to
demographics and tumor characteristics on breast cancer
diagnosis. These differences included the following out-
comes at diagnosis: age, race, histology, tumor and node
staging, and laterality. Second, we aimed to analyze differ-
ences pertaining to surgical treatment between patients in
the U.S. and China, using the same databases. These dif-
ferences included modified radical mastectomy versus rad-
ical mastectomy and reconstruction.
MATERIALS AND METHODS
Retrospective Study
Patient Selection in the U.S.
All patients with a diagnosis of breast cancer included in the
U.S. datawere included in this study. Patientswithadiagnosis
before 2000 and after 2010 were excluded from this study.
Within the years 2000–2010, therewere no specific exclusion
criteria. Methods of patient selection for the SEER database
can be found on the SEER website (http://seer.cancer.gov/
csr/1975_2010/).
Patient Selection in China
Data collection for patients with breast cancer in China was
conducted through the use of a multicenter retrospective
hospital-based database that focused on a cohort of Chinese
women with malignant primary breast cancer. In order to
acquire an extensive and representative cohort of patients for
this study that would be comparable to data acquired through
the U.S. SEER program, the nation of China was stratified into
seven geographic areas (north, northeast, central, south, east,
northwest, and southwest).The purpose of this approach was
to construct a large group of study patients that was
representative of both urban and rural areas and including
womenbelonging to both high and low socioeconomic classes
of diverse geographic regions. Within each of the seven
geographic regions, purposive sampling was used to choose
one tertiary public cancer hospital with certain inclusion
characteristics. These characteristics were as follows: chosen
hospitalswere thepublic cancer hospitals and regional referral
centers providing pathology diagnosis, surgery, radiotherapy,
medical oncologic treatment, and follow-up care for breast
cancerpatients.Chosenpublic cancerhospitalswere the larger
university hospitals specific to each region. Furthermore,
patient sources at each hospital had to contain patients from
the entire designated geographic study region. Finally, each
hospital chosen was located in a major city, based on the
premise that Chinese women with breast cancer tend to seek
treatment in bigger cities rather than less equipped rural
hospitals. With this hospital inclusion criteria, the list of
hospitals through which study patients were acquired in-
cluded CICAMS (north China); Liaoning Cancer Hospital
(northeast China); Second Xiangya Hospital, Central South
University (central China); Sun Yat-Sen University Cancer
Center (south China); Zhejiang Cancer Hospital (east China);
First Affiliated Hospital of Medical College, Xi’an Jiaotong
University (northwest China); and Sichuan Cancer Hospital
(southwest China). Further methodology detailing how this
enrollment process allowed for a cohort to be designed that
was representative of all geographic regionswithout selection
bias can be found in a previously published manuscript using
this database [4].
Each selected hospital in China provided the research team
withmedical records of patients diagnosedwith primary breast
cancer between 1999 and 2008. Patients diagnosed with
primary breast cancer and included in this study were required
to meet the following criteria: pathology-confirmed primary
breast cancer, inpatient admission data within the selected
monthof the studyhospital, and receipt (current or completed)
of treatment (surgical, medical, or radiotherapeutic) for the
diagnosed malignancy through the specific hospital site.
Patients with benign tumors or tumors suspicious for malig-
nancy without confirmation were excluded from this study [4].
From1999 to2008,45,200patientswithbreast cancerwere
treated in the 7 hospitals. We identified the study group by
random sampling of this population. Onemonthwas randomly
selectedwithineachyear (1999–2008),andall inpatientprimary
breast cancer cases for that month were reviewed. Inpatient
records fromJanuaryandFebruarywereexcluded fromrevision
because of potential confounding effects of Chinese New Year
vacation time on patient care. Each hospital collected data for
a minimum of 50 cases for each randomly chosen month
during 1999 to 2008, thus each hospital collected aminimumof
500 cases within these 10 years. We previously reported the
detailed methods used and the basic characteristics of the
patients included in this study [4].
www.TheOncologist.com ©AlphaMed Press 2015




Each Chinese hospital record was reviewed by local clerks
within each hospital according to our designated protocol that
was taught to clerks at CICAMS in Beijing. Standard case report
forms (CRFs) designedby theCICAMS research teamwereused
to acquire specific information from themedical record ofeach
included patient. The reliability and validity of the CRFs were
deemedappropriate throughapriorpilot study inwhichdetails
of hospitals and patient enrollment are further outlined [4].
Information gathered through CRFs included patient demo-
graphics, risk factors, diagnostic imaging test modalities and
results, tumor size and pathology, and surgical and chemo-
therapeutic treatments. Histology information was collected
through updated World Health Organization histological clas-
sification criteria.Afterdata collection, variablesacquiredwere
coded and categorized.
All Chinese data collected were stripped of any personal
identifiers according to approved study procedures and aggre-
gated into a secure master database to which only the primary
research team was granted access. Acquired SEER data were
received in an already deidentified manner. Patient consent for
this study was not required, given the lack of risks and retrospec-
tivedeidentified aspects. Both the Cancer Foundation of China
and Vanderbilt University institutional review boards granted
approval of the aforementioned methods.
Statistical Analysis
Descriptivestatistical testswereusedto illustrateandcompare
information regarding the following characteristics of both
AmericanandChinesepopulations: age, histology, thenumber
of examined and positive lymph nodes, laterality, stage and
tumor size on diagnosis, and radiation and surgical treatment.
Chemotherapy data were not analyzed, given the lack of specific
chemotherapeutic data in the SEER database.
Means and standard deviations were calculated for quanti-
tative variables from the Chinese and American databases.
Differences of rates were analyzed with Pearson chi-square
and/orFisher’sexacttests.GiventhattheChinesedatabasedid
not contain overall population data, the latest recorded in-
cidence of breast cancer was acquired through the National
Cancer Registry for 2009.
RESULTS
Patient Population
From 2000 to 2010, 384,262 patients were registered in the
breast cancer SEER database in the U.S., with 37 cases having
unlisted ages at diagnosis. From 1999 to 2008, 4,211 patients
were registered in the breast cancer CICAMS database in China,
with 3 cases having unlisted ages at diagnosis. The mean age at
diagnosis in the U.S.was 61.29 years, with an age range of 10 to
114 years. The mean age at diagnosis in China was 48.28 years,
with an age range of 21 to 85 years.The t tests showed that the
age at diagnosis in the U.S. was significantly higher than that of
China (t value 79.83, p, .001) (Table 1).
U.S. women included in the study population consisted of
the following races (n 5 384,262): 325,573 white (84.7%),
39,656black (10.3%),15,340AsianorPacific Islander(4.0%),926
American Indian/Alaska Native (0.2%), and 2,767 unknown
(0.7%). All women in China included in the study population
were of Chinese origin (n 5 4,211). Among the U.S. Asian or
Pacific Islander group, 1,928 were of Chinese origin and will be
referred to as Chinese Americans.The average age on diagnosis
of Chinese Americanswas 55.31 years, significantly higher than
that of Chinese women in China (p, .001) (Table 2).
The histological subtype with the highest frequency in
both the U.S. and China was infiltrating ductal carcinoma
(63.3% and 81.8%, respectively). A significantly higher pro-
portion of tumors originated in the right breast in patients in
the U.S. compared with those in China (Pearson chi-square
value 3.989, p 5 .046) (Table 3). A t test value of 225.546
indicated that primary tumors in China were significantly
largerondiagnosis than those in theU.S. (32.63vs. 21.57mm,
p, .001) (Table 1).
Tumor and Node Stages at Diagnosis
Overall, 288,187 U.S. patients, 3,455 Chinese patients, and
1,333 Chinese-American patients were included in the stage
analyses with stages I–IV (Table 2). The stage at diagnosis
occurring with the highest frequency in the U.S. was stage I
(47.45%), and the stage at diagnosis occurringwith the highest
frequency in Chinese-American patients was also stage I
(49.14%). The stage at diagnosis occurring with the highest
frequency in China was stage IIA (35.05%). A Pearson chi-square
value of 1372.53 demonstrated that patients in China were
diagnosed at a significantly higher stage than those in the U.S.,
including Chinese Americans (p, .001).
In patients with stage I malignancies, the average age at
diagnosis was 62.87 years in U.S. women, 56.47 years among
Chinese Americans, and 49.35 years in Chinese women. In
patients with stage IIA malignancies, the average ages at
diagnosis were 60.56, 54.7, and 49.44 years in U.S., Chinese-
American, and Chinese women, respectively (Table 2).
Stage I patients in theU.S.werediagnosedwith an average
tumor size of 7.31 mm compared with 10.83 mm in Chinese-
American women and 18.34 mm in women in China (p, .05)
(Table 2).
Positive Lymph Nodes
In the U.S. and China, the number of positive lymph nodes
with the highest frequency was zero (49.9% and 53.8%,
Table 1. Characteristics of breast cancer in the U.S. and China
Variants n Mean SD t test p value
Age at diagnosis (years)
U.S. 384,225 61.3 14.0 79.8 ,.001
China 4,208 48.3 10.5
Tumor size (mm)
U.S. 324,232 21.6 24.3 225.5 ,.001
China 2,522 32.6 21.6
Number of examined lymph nodes
U.S. 371,841 6.2 7.3 272.8 ,.001
China 4,124 14.4 7.3
Number of positive lymph nodes
U.S. 281,250 1.3 3.4 215.8 ,.001
China 4,131 2.6 5.1
Abbreviation: SD, standard deviation.
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respectively). A Pearson chi-square test value of 618.5 demon-
strated that the rate of having positive lymph nodes on
diagnosis in the U.S.was significantly lower than that of China
(32% vs. 49%, p , .001). A t test value of 215.84 indicated
that breast cancer patients in China were found to have a
significantly higher mean number of positive nodes in
comparison with those in the U.S. (2.59 vs. 1.31, p , .001)
(Table 1).
Surgical Method and Reconstruction
Inorder to createa standardizedcomparison,we includeddata
pertaining only to radical mastectomy and modified radical
mastectomy in this study with 90,547 U.S. patients and 3,739
Chinese patients. In the U.S., 98.3% of women at stage I
underwent a modified radical mastectomy compared with
1.7% undergoing a radical mastectomy. In China, 93.9% of
women at stage I underwent a modified radical mastectomy
and 6.1% underwent a radical mastectomy. Although 96.5%
of U.S. women at stage IV underwent modified radical
mastectomy, 77.3% of women in China underwent modified
radical mastectomy and 22.7% of women in China underwent
radical mastectomy. A Pearson chi-square value of 1,706.7
demonstrated that significantly more U.S. patients chose
modified radicalmastectomyandmoreChinesepatients chose
radical mastectomy (p, .001) (Table 4).
In the U.S., 9.9% of 74,502 of patients underwent im-
mediate reconstruction, whereas 0.02% of 4,185 patients
in China underwent immediate reconstruction. A Pearson
chi-square value of 455.1 demonstrated that a significantly
higher number of women in the U.S. underwent immediate
reconstruction, independent of stage, compared with China
(p, .001) (Table 4).
DISCUSSION
Discrepancies among diagnosis, characteristics, and surgical
treatment of breastmalignancies betweendevelopingnations
and the U.S. are vast.There has not been a comparison to date
between diagnosis and treatment patterns in China and those
Table 2. Characteristics of breast cancer by stage in U.S., Chinese, and Chinese-American women
Characteristic
Stage
p valueI IIA IIB IIIA IIIB IIIC IV
Number of patients, n (%)a
U.S. 136,745 (47.5) 68,948 (23.9) 29,265 (10.2) 20,699 (7.2) 7,403 (2.6) 10,204 (3.5) 14,923 (5.2) ,.001
Chinese 663 (19.2) 1,211 (35.1) 680 (19.7) 443 (12.8) 89 (2.6) 256 (7.4) 113 (3.3)
Chinese American 655 (49.1) 345 (25.9) 137 (10.3) 88 (6.6) 25 (1.9) 43 (3.2) 40 (3.0)
Age at diagnosis (years)b
U.S. 62.9 60.6 58.7 57.7 63.3 58.3 63.2 ,.001
Chinese 49.4 49.4 48.4 48.5 44.4 48.1 49.9
Chinese American 56.5 54.7 52.7 53.4 60.7 52.4 57.4
Tumor size (mm)b
U.S. 7.3 15.1 24.9 26.6 32.1 27.1 28.2 ,.001
Chinese 18.3 27.9 33.1 36.9 44.4 41.1 43.2
Chinese American 10.8 22.9 35.2 41.9 57.6 33.6 36.2
Number of examined lymph nodesb
U.S. 5.1 8.4 11.4 13.5 8.0 18.7 3.4 ,.001
Chinese 14.2 14.8 14.9 16.5 13.5 21.4 11.2
Chinese American 4.4 8.1 12.5 13.9 11.8 18.3 6.2
Number of positive lymph nodesb
U.S. 0 0.7 1.5 5.0 3.0 14.4 5.7 ,.001
Chinese 0 0.4 2.2 6.5 4.3 15.8 7.4
Chinese American 0 0.6 2.4 4.9 8.5 15.6 7.3
aThe chi-square test was done in three groups.
bThe analysis of variance test was done in three groups.
Table 3. Laterality of breast cancer in the U.S. and China
Location
Laterality, n (%)
Chi-square p valueRight Left Total
U.S. 186,500 (49.1) 193,426 (50.9) 379,926 (100) 3.989 .046
China 2,001 (47.5) 2,208 (52.5) 4,209 (100)
www.TheOncologist.com ©AlphaMed Press 2015
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of a developed nation [5]. In a multicenter systematic retro-
spectivecomparison,wefoundsignificantdifferencesbetween
characteristics and treatment of breast malignancies of pa-
tients in the U.S. and China, with the exception of tumor
histology. The following significant differences in breast
malignancies between patients in the U.S. and China on
diagnosis were validated: mean patient age is 13 years lower
inChina,meannumbersofbothexaminedandpositive lymph
nodes in China are approximately twice those of the U.S.,
and the U.S. exhibits a higher number of right-sided breast
malignancies [6]. Furthermore, stage at diagnosis is lower in
the U.S., mean size of the primary tumor is around 11 mm
smaller in the U.S., a greater proportion of women in China
receive radical versus modified radical mastectomies, and
fewer women in China undergo immediate breast recon-
struction.Themost common histology found in both the U.S.
and China was infiltrating ductal carcinoma (63.3% and
81.8%, respectively).
Given that there is not a standardized screening protocol
in China as there is in theU.S.,many Chinesewomenwho are
diagnosed with invasive malignancies at younger ages often
see a physician when they notice concerning changes in the
breasts [7]. In this retrospective study, we found that mean
age at diagnosis is significantly lower in China (48.28 years)
than in the U.S. (61.29 years). In addition, women in China
exhibited a significantly advanced average stage on diag-
nosis (stage IIA compared with stage I) based on primary
tumor size and a greater number of positive lymph nodes [8].
This study showed more examined lymph nodes in Chinese
patients than that in American patients (14.4 vs. 6.2, p ,
.001), probablydue to less useof sentinel lymphnodebiopsy
(SLNB) in China. It was shown thatmore than 95% caseswith
stages I–III in the Chinese database did not have SLNB,
indicating the underutilization of this method in China (data
not shown). Because there is no record of SLNB in the SEER
database, we could not compare this difference between
groups of patients. Although there is a current drive in China
to establish a national screening protocol similar to those
in developed nations, a noteworthy comparison is the
significantly lower average age of stage I patients in China
(49.35 vs. 62.87 years) and the larger tumor size of stage I
patients in China compared with stage I patients in the
U.S. (18.34 vs. 7.31 mm). Perhaps the issue is not a lack
of screening but rather more aggressive environmental
characteristics that cause larger, earlier malignancies and
fundamental differences between these tumors despite the
similar infiltrating ductal carcinoma demonstrated in this
study. To investigate this, we analyzed variables based on
stage for Chinese-American women through SEER data [1]
and found that Chinese-American women were diagnosed
most frequently as stage I (49.14%) at a mean age higher
than Chinese women (56.47 vs. 49.35 years) and with a
tumor size significantly smaller than that of Chinese women
(10.83 vs. 18.34 mm). These results encourage the theory
that environmental factors and lack of screening in China
significantly contribute to the more advanced malignancies
diagnosed.
Because of the later stages at diagnosis, a higher pro-
portion of women in China do not undergo surgery, or they
undergo radical mastectomy rather than modified radical
mastectomy, according to our data. We believe that this
difference is partly due to conservative patient choice of
surgicalmethod in China, after the surgeon explains both the
Halsted radical mastectomy and modified radical mastectomy.
We believe the difference is also partly due to more ad-
vanced tumors in China, necessitating more aggressive
surgical excision. Furthermore, a significantly higher number
of women undergo immediate reconstruction in the U.S.
Table 4. Surgery methods in the U.S. and China
Surgical methods
Stage
I II III IV
Radical mastectomy
U.S. 388 (1.7) 568 (1.7) 490 (2.1) 94 (3.5)
China 34 (6.1) 140 (7.8) 140 (18.6) 20 (22.7)
Modified radical mastectomy
U.S. 22,679 (98.3) 32,860 (98.3) 22,403 (97.9) 2,579 (96.5)
China 521 (93.9) 1,652 (92.2) 614 (81.4) 68 (77.3)
Chi-square test 61.005 322.693 759.61 74.649
p value ,.001 ,.001 ,.001 ,.001a
No reconstruction
U.S. 24,399 (91.7) 17,121 (88.7) 7,190 (89.2) 2,738 (97.6)
China 661 (99.8) 1,890 (100.0) 786 (100.0) 113 (100.0)
Reconstruction
U.S. 2,200 (8.3) 2,183 (11.3) 869 (10.8) 67 (2.4)
China 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Chi-square test 57.381 238.274 93.988 1.800
p value ,.001 ,.001 ,.001 .180a
aCorrected chi-square test.
Data are shown as number (percentage) except as noted otherwise.
©AlphaMed Press 2015
TheOncologist®
1048 Breast Cancer Disparities Between the U.S. and China
CM
E
(9.9%) compared with women in China (0.02%). Reconstruc-
tionbeyond the immediate settingwasnotanalyzedbecause
of the lack of these data in our Chinese database. This trend
of decreased surgical and reconstructive treatment and
operations that are more aggressive than those in the U.S.
could be multifactorial. One reason could be the higher
percentage of metastatic advanced stage tumors on diag-
nosis in China compared with the U.S. Given the advanced
stages of these tumors, surgical and/or radiation treatment
would not be curative. Regarding reconstructive treatment,
this aspect of care is not covered by insurance in China, and
that could contribute to the extremely low rate of treatment
demonstrated in this study.
A notable consideration is the conservative nature of
Chinese patients, particularly those of lower socioeconomic
status in rural areas [9, 10]. Social stigmas regarding breast
cancer, surgery, and reconstruction likely play a role in more
women opting out of surgical treatment. This could be com-
pounded by a lack of patient education regarding the efficacy
of these surgical treatments [11, 12]. Radical mastectomies
may be performed at a higher rate in China because of the
advanced stages at which Chinese women are diagnosed
due to a lack of health care access, patient education, and
adequate screening, among other factors [13, 14]. Although
we did not analyze differences between rural and urban
groups regarding choice of radical mastectomy versus modi-
fied radical mastectomy, a prior study using this database
established thatbreast-conservingsurgery increasedby15%in
areas of higher socioeconomic status compared with only 6%
in areas of lower socioeconomic status [15]. Further studies
regarding the specific reasons for these surgical trends must
be conducted to increase the number of womenwho undergo
less aggressive surgical treatment, perhaps with earlier diag-
nosis. Future studies should also address possible reasons
for minimal reconstruction in China, aside from insurance
coverage, to address the needs of patients regarding self-
image. Finally, given the overall advancement of chemother-
apy, endocrine therapy, and targeted therapy, further studies
comparing such treatment in China and the U.S. must be
conducted toassess howtooptimizeboth surgical andmedical
aspects of care in China.
Our values of tumor characteristics and surgical treat-
ment reported over a similar 10-year period demonstrate
significant discrepancies between diagnosis and treatment
of breast malignancies in China compared with the U.S.
These discrepancies have a direct influence on the in-
creasing rates of incidence in China in recent years [16]. It is
likely that several of these differences pertaining to the
advanced nature of malignancies on diagnosis in China are
related to the lack of patient knowledge and a standardized
screening protocol [17], especially when observing our
results comparing Chinese-American patients to those in
China. Differences pertaining to surgical and reconstructive
treatments could be related to the conservative nature
of Chinese women or to the lack of knowledge regarding
surgical options and efficacy. These differences can also
reflect the advanced nature of Chinese malignancies. A
limitationof this study is the slightdifference in timeperiods
analyzedbetween the twonations. A strengthof this study is
the use of extensive study cohorts from both nations,
enabling high statistical power of outcomes. A necessary
follow-up of this study includes acquiring information
regarding patient knowledge and preferences in China to
address screening and surgical discrepancies. Additional
studies must explore the aforementioned differences in
stage I tumor characteristics between China and the U.S.,
specifically including Chinese-American patients.
CONCLUSION
Although the current literature suggests inadequate screen-
ing of breast malignancies and subsequently higher rates of
mortality in developing nations such as China, a large-scale
study comparing specific diagnostic-related differences
between China and a developed nation with lower mortality
rates has not been conducted. This study demonstrated that
women in China are diagnosed at significantly younger ages,
with larger, higher stage tumors and more positive lymph
nodes. A smaller proportion of women in China undergo
surgical and immediate reconstructive treatment compared
with women in the U.S., and a higher proportion of Chinese
women undergo radical versus modified radical mastecto-
mies. Follow-up studies are needed to understand why
Chinese women acquire breast cancers at an average of 13
years younger than their femaleU.S. counterparts. Follow-up
studies are also needed to further characterize the reasons
for these global health care discrepancies and could dra-
matically affect comorbidity and mortality rates for breast
cancer in China, if addressed.This study provides descriptive
knowledge that health care providers and policy makers can
use to address specific differences in treatment and ultimately
reduce the international disease burden of breast cancer.
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